PMID- 35271583
OWN - NLM
STAT- MEDLINE
DCOM- 20220421
LR  - 20220421
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 3
DP  - 2022
TI  - Predicting treatment response and clinicopathological findings in lupus nephritis 
      with urine epidermal growth factor, monocyte chemoattractant protein-1 or their 
      ratios.
PG  - e0263778
LID - 10.1371/journal.pone.0263778 [doi]
LID - e0263778
AB  - INTRODUCTION: There is a need for sensitive and specific biomarkers to predict 
      kidney damage and therapeutic response in lupus nephritis (LN). Monocyte 
      chemoattractant protein-1 (MCP-1) and epidermal growth factor (EGF) are cytokines 
      with divergent roles. EGF or EGF/MCP1 ratio have been shown to correlate with 
      prognosis in primary glomerulonephritis, but there is limited information in 
      lupus nephritis (LN). This study evaluated the roles of MCP-1, EGF or their ratio 
      as biomarkers of histopathology and response to treatment in LN. METHODS: This 
      was a cross-sectional and observational study. Baseline urine MCP-1 and EGF 
      levels in systemic lupus erythematosus (SLE) patients and controls (total n = 
      101) were compared, and levels were correlated with clinicopathological findings 
      and subsequent response to treatment. RESULTS: MCP-1 was higher in active LN (n = 
      69) compared to other SLE groups and controls, whereas EGF was not different. 
      MCP-1 correlated with disease activity (proteinuria, renal SLEDAI, classes 
      III/IV/V, and high activity index.) By contrast, EGF correlated with eGFR, but 
      not with proteinuria, activity index, or class III/IV/V. MCP-1 was higher, and 
      EGF was lower in high chronicity index. EGF/MCP-1 decreased with greater 
      clinicopathological severity. In a subgroup with proliferative LN who completed 
      six months of induction therapy (n = 41), EGF at baseline was lower in 
      non-responders compared to responders, whereas MCP-1 was similar. By 
      multivariable analysis, baseline EGF was independently associated with subsequent 
      treatment response. Area under the curve for EGF to predict response was 0.80 
      (0.66-0.95). EGF >/= 65.6 ng/ mgCr demonstrated 85% sensitivity and 71% specificity 
      for response. EGF/MCP-1 did not improve the prediction for response compared to 
      EGF alone. CONCLUSION: MCP-1 increased with disease activity, whereas EGF 
      decreased with low GFR and chronic damage. Urine EGF may be a promising biomarker 
      to predict therapeutic response in LN. EGF/MCP-1 did not improve the prediction 
      of response.
FAU - Ngamjanyaporn, Pintip
AU  - Ngamjanyaporn P
AD  - Faculty of Medicine Ramathibodi Hospital, Department of Medicine, Mahidol 
      University, Bangkok, Thailand.
FAU - Worawichawong, Suchin
AU  - Worawichawong S
AUID- ORCID: 0000-0003-1238-1536
AD  - Faculty of Medicine Ramathibodi Hospital, Department of Pathology, Mahidol 
      University, Bangkok, Thailand.
FAU - Pisitkun, Prapaporn
AU  - Pisitkun P
AD  - Faculty of Medicine Ramathibodi Hospital, Department of Medicine, Mahidol 
      University, Bangkok, Thailand.
FAU - Khiewngam, Khantong
AU  - Khiewngam K
AD  - Faculty of Medicine Ramathibodi Hospital, Department of Medicine, Mahidol 
      University, Bangkok, Thailand.
FAU - Kantachuvesiri, Surasak
AU  - Kantachuvesiri S
AD  - Faculty of Medicine Ramathibodi Hospital, Department of Medicine, Mahidol 
      University, Bangkok, Thailand.
FAU - Nongnuch, Arkom
AU  - Nongnuch A
AUID- ORCID: 0000-0003-3876-9432
AD  - Faculty of Medicine Ramathibodi Hospital, Department of Medicine, Mahidol 
      University, Bangkok, Thailand.
FAU - Assanatham, Montira
AU  - Assanatham M
AUID- ORCID: 0000-0002-3835-175X
AD  - Faculty of Medicine Ramathibodi Hospital, Department of Medicine, Mahidol 
      University, Bangkok, Thailand.
FAU - Sathirapongsasuti, Nuankanya
AU  - Sathirapongsasuti N
AD  - Faculty of Medicine Ramathibodi Hospital, Section of Translational Medicine, 
      Mahidol University, Bangkok, Thailand.
FAU - Kitiyakara, Chagriya
AU  - Kitiyakara C
AUID- ORCID: 0000-0001-6340-3534
AD  - Faculty of Medicine Ramathibodi Hospital, Department of Medicine, Mahidol 
      University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220310
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 62229-50-9 (Epidermal Growth Factor)
SB  - IM
MH  - Biomarkers/urine
MH  - Chemokine CCL2/urine
MH  - Cross-Sectional Studies
MH  - Epidermal Growth Factor/urine
MH  - Female
MH  - Humans
MH  - *Lupus Erythematosus, Systemic/drug therapy
MH  - *Lupus Nephritis/pathology
MH  - Male
MH  - Proteinuria
PMC - PMC8912200
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/03/11 06:00
MHDA- 2022/04/22 06:00
PMCR- 2022/03/10
CRDT- 2022/03/10 17:14
PHST- 2021/08/12 00:00 [received]
PHST- 2022/01/26 00:00 [accepted]
PHST- 2022/03/10 17:14 [entrez]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/04/22 06:00 [medline]
PHST- 2022/03/10 00:00 [pmc-release]
AID - PONE-D-21-26188 [pii]
AID - 10.1371/journal.pone.0263778 [doi]
PST - epublish
SO  - PLoS One. 2022 Mar 10;17(3):e0263778. doi: 10.1371/journal.pone.0263778. 
      eCollection 2022.